Loading
A phase 3 trial of Glasdegib in Acute myeloid leukaemia, run by University Hospital Heidelberg, recorded as terminated on the registry.
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) is a phase 3 interventional study registered as NCT04093505 by University Hospital Heidelberg, with 28 participants recorded, started 2021-04-01 and due to reach its primary completion in 2022-06-15. Interventions recorded: Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib, Placebo Oral Tablet. Conditions recorded: Acute Myeloid Leukemia.
Linked to the drug Glasdegib because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glasdegib, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Glasdegib and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/